NASDAQ: INAB
In8bio Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their INAB stock forecasts and price targets.

Forecast return on equity

Is INAB forecast to generate an efficient return?

Company
373.46%
Industry
354.92%
Market
211.58%
INAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INAB forecast to generate an efficient return on assets?

Company
293.75%
Industry
117.87%
INAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INAB earnings per share forecast

What is INAB's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.14
Avg 2 year Forecast
-$2.52
Avg 3 year Forecast
$2.79

INAB revenue forecast

What is INAB's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$2.0M
Avg 3 year Forecast
$26.8M

INAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INAB$2.46N/AN/A
CMMB$1.79$25.00+1,296.65%Buy
ABP$4.22N/AN/A
BOLT$5.79$7.00+20.90%Buy
PHIO$1.09$14.00+1,184.40%Buy

In8bio Stock Forecast FAQ

What is INAB's earnings growth forecast for 2026-2028?

(NASDAQ: INAB) In8bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.61%.

In8bio's earnings in 2026 is -$20,658,000.On average, 5 Wall Street analysts forecast INAB's earnings for 2026 to be -$9,895,362, with the lowest INAB earnings forecast at -$13,216,371, and the highest INAB earnings forecast at -$6,617,917. On average, 6 Wall Street analysts forecast INAB's earnings for 2027 to be -$11,664,311, with the lowest INAB earnings forecast at -$16,350,149, and the highest INAB earnings forecast at -$4,330,843.

In 2028, INAB is forecast to generate $12,920,696 in earnings, with the lowest earnings forecast at -$10,082,592 and the highest earnings forecast at $55,473,720.

If you're new to stock investing, here's how to buy In8bio stock.

What is INAB's revenue growth forecast for 2026-2028?

(NASDAQ: INAB) In8bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.

In8bio's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast INAB's revenue for 2026 to be $0, with the lowest INAB revenue forecast at $0, and the highest INAB revenue forecast at $0. On average, 6 Wall Street analysts forecast INAB's revenue for 2027 to be $9,463,437, with the lowest INAB revenue forecast at $0, and the highest INAB revenue forecast at $38,970,636.

In 2028, INAB is forecast to generate $124,113,759 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $383,296,990.

What is INAB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: INAB) forecast ROA is 293.75%, which is higher than the forecast US Biotechnology industry average of 117.87%.

What is INAB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: INAB) In8bio's current Earnings Per Share (EPS) is -$5.39. On average, analysts forecast that INAB's EPS will be -$2.14 for 2026, with the lowest EPS forecast at -$2.85, and the highest EPS forecast at -$1.43. On average, analysts forecast that INAB's EPS will be -$2.52 for 2027, with the lowest EPS forecast at -$3.53, and the highest EPS forecast at -$0.93. In 2028, INAB's EPS is forecast to hit $2.79 (min: -$2.18, max: $11.97).

What is INAB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: INAB) forecast ROE is 373.46%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.